University of Maryland, Baltimore · PharmacologyWang Lab
Hongbing Wang · Baltimore, Maryland
Research Focus
Dr. Hongbing Wang's lab focuses on improving cancer treatments, particularly for aggressive types like triple-negative breast cancer. The research aims to enhance the effectiveness of standard chemotherapy drugs while reducing their harmful side effects. By studying how dual activation of specific proteins can improve drug metabolism and decrease toxicity, the lab hopes to develop better therapies for patients suffering from resistant cancers.
triple-negative breast cancerCAR activationNrf2 activationchemotherapy optimizationdrug metabolismcardiotoxicityprodrug activation
Research Aims
3AIM 01Determine how novel hCAR/Nrf2 dual activators affect cyclophosphamide metabolism and doxorubicin detoxification.
AIM 02Evaluate the combined effects of cyclophosphamide and doxorubicin with hCAR/Nrf2 dual activators in a multicellular model.
AIM 03Investigate the therapeutic outcomes of hCAR/Nrf2 activation on cyclophosphamide/doxorubicin treatment in transgenic mice.
Skills the Lab Values
cell culturemouse modelsmulticellular co-culture techniqueschemical synthesishigh-performance liquid chromatography (HPLC)Western blotRNA extraction and quantificationreal-time PCR
Output against the department
Publications290top 27% of dept.125th of 462
this lab
most publishedleast published
Citations11ktop 35% of dept.164th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.